Cardiff Oncology, Inc. CRDF

Cardiff Oncology reported second quarter earnings including revenue, net loss and operational updates for the period. Quarterly earnings supply financial metrics that can shift near-term investor sentiment and valuation.

Cardiff Oncology reported second quarter 2026 financial results and provided a business update. Quarterly results and business updates deliver financial metrics that moderately shift near-term valuation and sentiment for clinical-stage biotech firms.

Cardiff Oncology, Inc. (CRDF) announces a $10 million registered direct offering. $10 million registered direct offering adds capital and affects share structure.

Cardiff Oncology, Inc. (CRDF) stock faces questions of undervaluation amid ongoing legal uncertainty while its cancer drug pipeline holds future potential. Legal uncertainty combined with cancer drug potential points to moderate effects on financial performance and investor sentiment.

Cardiff Oncology Phase II trial update shows extended survival advantage in oncology patients. Positive Phase II survival extension data can materially lift valuation and trial momentum for CRDF.

Cardiff Oncology announces positive results from its randomized Phase 2 trial of Onvansertib in first-line RAS-mutated metastatic colorectal cancer presented at the 2026 ASCO Annual Meeting. Positive Phase 2 data for lead asset at major oncology conference signals major clinical progress likely to drive significant investor interest and valuation upside.

Cardiff Oncology reported its first quarter 2026 financial results. Quarterly results provide updates on financial position and operations that can moderately influence investor views.

Cardiff Oncology schedules a webcast to present updated Phase 2 CRDF-004 results for Onvansertib in first-line RAS-mutated metastatic colorectal cancer. Upcoming Phase 2 data readout for lead asset Onvansertib can materially shift clinical outlook and valuation.

Cardiff Oncology, Inc. (CRDF) reported first quarter 2026 financial results and provided a business update. Quarterly earnings reports with business updates moderately influence financial performance and investor sentiment.

Cardiff Oncology to host Key Opinion Leader discussion on onvansertib’s promising single-agent activity. KOL discussion on promising onvansertib data may moderately boost investor sentiment and affect short-term market performance.

Cardiff Oncology to present updated Phase 2 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer at a rapid oral session during ASCO 2026. Oral presentation of updated Phase 2 data at ASCO signals strong clinical progress in key oncology indication, likely boosting CRDF investor sentiment and valuation.

Cardiff Oncology, Inc. (CRDF) hosted a Key Opinion Leader event focused on colorectal cancer, featuring expert discussions on treatment advancements and the company's onvansertib program. KOL event spotlights CRDF's colorectal cancer pipeline, likely generating moderate investor interest without fundamentally altering trajectory.

Cardiff Oncology showcased Onvansertib in a webinar, highlighting a 72% objective response rate signal from its Phase II trial in RAS-mutant metastatic colorectal cancer. 72% ORR signal in Phase II RAS-mutant mCRC trial represents significant positive clinical progress for Onvansertib, likely boosting CRDF's valuation and investor sentiment.

Cardiff Oncology to host Key Opinion Leader discussion focusing on first-line RAS-mutated metastatic colorectal cancer. KOL event highlights focus on lead indication in RAS-mutated mCRC, potentially impacting investor sentiment and competitive positioning.

Cardiff Oncology presented Onvansertib data at Oppenheimer conference, achieving 72% overall response rate in RAS-mutant metastatic colorectal cancer patients. 72% ORR in RAS-mutant mCRC signals strong efficacy for Onvansertib, likely boosting investor sentiment and accelerating development.

Cardiff Oncology, Inc. (CRDF) released its Q4 earnings snapshot. Q4 earnings snapshots reveal financial results that moderately influence investor sentiment and stock performance.

Cardiff Oncology, Inc. (CRDF) reported full year 2025 financial results and provided a business update. Full-year financial results and business updates affect key financial performance and pipeline progress but are balanced by clinical-stage uncertainties.

Cardiff Oncology, Inc. has appointed a new CEO who presented the Phase II clinical trial results for its lead drug candidate, which showed promising efficacy in treating patients with a specific type of cancer. The data indicates potential for further development and could attract investor interest. The company aims to advance its clinical programs and enhance its market position under the new leadership. The new CEO's presentation of Phase II results could significantly influence Cardiff Oncology's strategic direction and investor sentiment.

Cardiff Oncology, Inc. (CRDF) has seen a significant decline of 43.9% following advancements in its drug onvansertib and a reshuffling of its leadership team. The company is focusing on its clinical trials and strategic direction, but the recent changes have raised concerns among investors, leading to a sharp drop in stock value. The leadership changes and drug advancements may influence investor sentiment and operational focus, but the overall impact is expected to be limited.

Cardiff Oncology, Inc. has appointed an interim CEO and selected a 30mg regimen of Onvansertib for its upcoming registrational study in metastatic colorectal cancer (mCRC) scheduled for 2026. This decision marks a strategic move as the company aims to advance its clinical development program and enhance its market position in oncology. The appointment of an interim CEO and the selection of a specific treatment regimen for a pivotal study are significant strategic decisions that could influence the company's future trajectory and investor sentiment.

Cardiff Oncology, Inc. announced positive results from its randomized Phase 2 trial of Onvansertib in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). The trial demonstrated improved progression-free survival rates compared to standard treatment, indicating Onvansertib's potential as an effective therapy for this patient population. The company plans to advance the development of Onvansertib based on these encouraging findings. Positive trial results could significantly enhance Cardiff Oncology's market position and investor sentiment.

Cardiff Oncology, Inc. has announced changes in its executive leadership team as it prepares to transition into late-stage clinical development. The company aims to enhance its strategic direction and operational efficiency during this critical phase of growth. Leadership changes during a transition to late-stage clinical development can significantly impact strategic direction and investor sentiment.

Cardiff Oncology, Inc. (CRDF) is highlighted as one of three promising penny stocks with market capitalizations below $600 million. The company focuses on developing innovative cancer therapies, particularly its lead product candidate, onvansertib, which targets KRAS mutations. Recent advancements in clinical trials and partnerships have positioned CRDF favorably within the oncology sector. Investors are encouraged to consider the potential growth opportunities associated with CRDF's unique approach to cancer treatment. Recent advancements in clinical trials and partnerships could significantly alter the company's trajectory and investor sentiment.

Cardiff Oncology, Inc. (CRDF) is highlighted as one of three penny stocks with a market capitalization exceeding $100 million. The company focuses on developing innovative cancer therapies, particularly its lead product candidate, onvansertib, which is in clinical trials for various cancers. The article emphasizes the potential for growth in the oncology sector and the importance of market capitalization in assessing investment opportunities. The company's ongoing clinical trials and focus on innovative therapies may moderately influence its financial performance and market positioning.

Cardiff Oncology, Inc. (NASDAQ:CRDF) saw its market capitalization increase by US$19 million last week, benefiting institutional investors, but retail investors gained the most from this rise. The surge in market cap reflects positive sentiment and potential growth prospects for the company. The increase in market cap indicates a moderately noticeable influence on investor sentiment and potential financial performance.

Cardiff Oncology, Inc. (CRDF) has initiated coverage on its combination therapy, which has shown superior response rates in clinical trials. The therapy targets specific cancer types and aims to enhance treatment efficacy. Analysts highlight the potential for this approach to improve patient outcomes and position CRDF favorably in the oncology market. The company is expected to leverage this innovative strategy to attract investor interest and drive future growth. The combination therapy's superior response rates could significantly enhance CRDF's competitive positioning and market appeal.

Cardiff Oncology, Inc. announced clinical data from an investigator-sponsored trial of Onvansertib in patients with Chronic Myelomonocytic Leukemia (CMML) at the ASH 2025 conference. The trial results demonstrated promising efficacy and safety profiles, highlighting Onvansertib's potential as a treatment option for CMML. The data may pave the way for further development and regulatory considerations for Onvansertib in this indication. Promising clinical data could significantly enhance Cardiff Oncology's market position and investor sentiment.

Cardiff Oncology, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference, highlighting its ongoing commitment to advancing cancer therapies. The presentation is expected to provide insights into the company's strategic direction and recent developments in its clinical programs. Participation in a significant healthcare conference may enhance visibility and investor interest but is unlikely to lead to immediate substantial changes in market performance.

Cardiff Oncology, Inc. reported its financial results for the third quarter of 2025, highlighting key metrics and developments in its ongoing clinical programs. The company provided updates on its pipeline, including progress in trials and collaborations aimed at advancing its oncology treatments. Management emphasized their commitment to innovation and strategic partnerships to enhance growth and shareholder value. Significant updates on clinical programs and strategic partnerships are likely to influence future performance and investor sentiment.

Cardiff Oncology, Inc. reported its Q3 earnings, highlighting key financial metrics and operational updates. The company continues to advance its clinical programs and maintain a focus on developing innovative cancer therapies. Investors are keenly observing the implications of these results on future growth and market positioning. Q3 earnings results may moderately influence financial performance and investor sentiment.